Polypeptide With Localisation/Targeting Motif TRIZ Cases

Segmented synthetic receptors release functional domains via proteolytic cleavage to resolve specificity versus versatility trade-offs in targeted therapies.

Reversible binding agents modulate signaling duration and strength to prevent uncontrolled proliferation during targeted cell culture.

Humanized anti-BCMA antibodies enable CAR-T cells to kill resistant myeloma cells, overcoming relapse.

Incorporating target binding sites into extracellular vesicle surface proteins via localized mutagenesis resolves low cellular uptake and stability issues.

Segmented NKG2D receptors bind engineered ligands to deliver cytokines, resolving toxicity from uncontrolled activation.

Self-inactivating adeno-associated virus vectors reduce immunogenicity and off-target effects by diminishing CRISPR expression after editing.

Chimeric PD-1 receptors on engineered immune cells enhance tumor penetration and activate cytotoxic T cells within immunosuppressive microenvironments.

Engineered CAR fusion proteins direct regulatory T-cells to suppress cytotoxic responses against specific HLA molecules, resolving HvG disease rejection.

A molecular recognition element links a direct electron transfer oxidoreductase to an electrode for electrochemical signal detection.

Engineered immune cells express dual chimeric antigen receptors to recognize fibroblast activation protein and tumor-associated antigens.

A chimeric protein induces STAT-5 signaling via dimerization to support cell survival.

Multispecific TIM3 antibodies and chimeric antigen receptors overcome limited binder avidity to enhance antitumor immunity.

Humanized anti-ROR1 antibodies reduce immunogenicity while maintaining high affinity through parameter changes and copying principles.

Chicken TAPBPR chimeras enable broad HLA supertype coverage, overcoming human protein limitations.

Phage-displayed anti-ROR2 antibodies achieve high binding affinity and specificity, resolving cross-reactivity side effects with ROR1.

Chimeric antigen receptor polypeptides target TLR9-expressing myelodysplastic syndrome cells, expanding treatable patient populations beyond del5q subtypes.

C-terminal peptides regulate BKCa channel trafficking to avoid off-target effects from lipophilic small molecules.

Structure-based peptide inhibitors bind to alpha-synuclein molecules to block amyloidogenic aggregation and cytotoxicity.

A Cas13-TIF fusion protein recruits ribosomes to specific mRNA transcripts.

Flow cytometry replaces electron microscopy to profile single exosome biomarkers, resolving low sensitivity and high cost barriers in molecular profiling.

Engineered microorganisms express larazotide peptides to stabilize tight junction proteins and maintain gastrointestinal epithelial integrity.

A single-chain RBD-dimer protein utilizes flexible linker sequences to connect monomers, enhancing immunogenicity and expression stability.

TLR9-derived inhibitory peptides bind the TLR9 TIR domain to block signal transduction, addressing the lack of specific inhibitors for inflammatory diseases.

A chimeric polypeptide induces constitutive cytokine signaling via an antigen-binding domain and receptor endodomain.

Anti-MICA antibodies block NKG2D receptor saturation on tumor cells, restoring NK cell cytotoxic activity and enabling effective immune-mediated tumor lysis.

Engineered T cell receptors bind specifically to the NY-ESO-1 peptide presented by HLA-A*02:01 on tumor surfaces.

Recombinant SP-B peptides produced in plant cells lower surface tension on lipid bilayers.

Glycoengineered antibodies bind to conserved N-glycan epitopes on the HIV envelope, resolving the contradiction between long-term protection and viral mutation.

A mitochondrial targeted RNA expression system directs therapeutic RNAs to mitochondria using specific promoter and leader sequences.

Orthogonal site-specific DNA recombinases create nucleic acid logic gates in mammalian cells.

Membrane-anchored TRAIL-CD40L fusion protein enhances cancer cell killing activity through targeted apoptosis induction.

An anti-GD TCR CAR binds gamma delta T cells to induce specific cytotoxicity against malignancies.

A liver-targeting pharmaceutical composition delivers antigens to hepatocytes via receptor binding.

A minimum Orthoreovirus muNS region forms inclusions to recruit and purify interacting proteins.

Isolated CD33-binding proteins target acute myeloid leukemia cells via specific heavy and light chain complementarity determining regions.

Site-specific CRISPR-Cas9 editing replaces viral vectors to eliminate oncogenic risks and production delays.

Chimeric immunogens merge RSV and hMPV antigenic sites to overcome the lack of cross-protective immunity against both viruses.

Magnetic bead selection isolates CD3-CD14- progenitors from peripheral blood, enabling cost-effective CAR T generation without complex thymic cultures.

Computational design of ultra-stable transmembrane domains enhances target-cell cytotoxicity in engineered T cells.

Bispecific binding agents recruit membrane-associated ubiquitin E3 ligases to target surface proteins for degradation.

Peptides induce immune tolerance to chimeric antigen receptors, extending cell persistence in adoptive therapy.

Chimeric costimulatory receptors redirect TNFα signaling to promote T cell stimulation and persistence, bypassing impaired antigen presentation.

Gene editing disrupts exhaustion regulators to enhance antitumor potency against glioblastoma.

Chimeric antigen receptors with anti-TIM3 binding agents enable targeted killing of TIM3-expressing cancers via adoptive cell transfer.

Hybrid allosteric receptor stem cells resolve inadequate homing and poor differentiation in acute myocardial infarction treatment.

Engineered macrophages use chimeric receptors to kill cancer cells, avoiding fratricide and T cell aplasia risks.

Secretable PD-1 and IFNα2a fusion protein overcomes tumor microenvironment immunosuppression to improve solid tumor therapy efficacy.

Replacing the conventional CD8 backbone with a CD99-derived structure enhances immune synapse stability, overcoming low therapeutic efficiency in solid tumors.